阿波罗逆转了停机计划,确保了410万美元的安全,任命了新的领导人,并继续其第二阶段的癌症药物APL-101试验。 Apollomics reversed shutdown plans, securing $4.1M, appointing new leadership, and continuing its Phase 2 trial for cancer drug APL-101.

Apollomics， Inc. 已改变其停止运营的计划，于 2025 年 9 月 3 日获得了 410 万美元的私人投资，并任命了包括首席执行官 Howard Chen 在内的新领导层。 Apollomics, Inc. has reversed its plan to halt operations, securing $4.1 million in private investment on September 3, 2025, and appointing new leadership, including CEO Howard Chen. 该公司将继续其全球阶段2SPARTA试验APL-101(vebreltinib)肺癌和脑癌试验,所有临床合同都在运作和支付。 The company will continue its global Phase 2 SPARTA trial of APL-101 (vebreltinib) for lung and brain cancers, with all clinical contracts active and paid. 阿波罗计划到10月31日增长到15名员工, 将员工从中国转移至美国及台湾, Apollomics plans to grow to 15 employees by October 31, shifting staff from China to the U.S. and Taiwan, and aims to pursue regulatory submissions in Southeast Asia, the Middle East, and other markets using existing approvals in China. 12个月的业务计划支持正在进行的发展。 A 12-month business plan supports ongoing development.